Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma Group (MREO) Accumulated Expenses: 2020-2024

Historic Accumulated Expenses for Mereo BioPharma Group (MREO) over the last 5 years, with Dec 2024 value amounting to $4.1 million.

  • Mereo BioPharma Group's Accumulated Expenses rose 16.69% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 16.69%. This contributed to the annual value of $4.1 million for FY2024, which is 25.54% down from last year.
  • Per Mereo BioPharma Group's latest filing, its Accumulated Expenses stood at $4.1 million for FY2024, which was down 25.54% from $5.5 million recorded in FY2023.
  • In the past 5 years, Mereo BioPharma Group's Accumulated Expenses ranged from a high of $5.5 million in FY2023 and a low of $4.1 million during FY2024.
  • For the 3-year period, Mereo BioPharma Group's Accumulated Expenses averaged around $5.0 million, with its median value being $5.4 million (2022).
  • As far as peak fluctuations go, Mereo BioPharma Group's Accumulated Expenses grew by 5.40% in 2022, and later dropped by 25.54% in 2024.
  • Over the past 5 years, Mereo BioPharma Group's Accumulated Expenses (Yearly) stood at $5.4 million in 2020, then decreased by 3.87% to $5.2 million in 2021, then climbed by 5.40% to $5.4 million in 2022, then rose by 0.57% to $5.5 million in 2023, then declined by 25.54% to $4.1 million in 2024.